Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ICCC vs IRIX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ICCC Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–1 Matrix Metrics)

ICCC Overall Winner 6-Pillar Tally: ICCC 3 – 2 IRIX (1 Tie) Matrix Metrics: ICCC 8 – 1 IRIX

As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Iridex Corp (IRIX) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ICCC carries a Unified Composite Score of 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin), whereas IRIX carries 51.8/100 (HOLD) at $0.69 (N/M Forward P/E, -5.4% operating margin).

  • Composite vs. Pillar Nuance: While IRIX currently prints a higher short-term Unified Composite Score (51.8/100 HOLD vs. ICCC 43.8/100 HOLD), ICCC captures the overall institutional head-to-head verdict (8–1 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (15.2% vs. -5.4% operating margin) and revenue trajectory (+11.5% vs. -7.4% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ICCC vs IRIX
ICCC NASDAQ Head-to-Head Winner
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap $97.7M
TTM Revenue $67M
Forward P/E N/M
Beta / 30D Vol 0.24β · 46% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 15.0 Fund 48.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.9% over 20 days), RSI 68
RSI-14: 67.5 · SMA20: $10.37 · SMA50: $10.13
IRIX NASDAQ
Iridex Corp
Electromedical & Electrotherapeutic Apparatus
$0.69
-0.32% 1D
Market Cap $12.1M
TTM Revenue $52M
Forward P/E N/M
Beta / 30D Vol 0.66β · 58% Vol
Unified Composite Score
51.8 / 100 HOLD
Tech 52.0 Fund 65.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.2 · SMA20: $0.72 · SMA50: $0.71

6-Pillar Scorecard Institutional Category Breakdown (ICCC 3 – 2 IRIX)

Columns: Metric · ICCC · IRIX
1. Valuation Multiples IRIX
Forward P/E N/M N/M
Trailing P/E 56.6x N/M
PEG Ratio N/M 0.94x
EV / Revenue 1.6x 0.2x
2. Growth & Scale ICCC
Revenue Growth (YoY) +11.5% -7.4%
Earnings Growth (YoY) +259.9% +0.0%
TTM Revenue (USD) $67M $52M
Market Cap $97.7M $12.1M
3. Profitability & Quality ICCC
Gross Margin 40.3% 35.9%
Operating Margin 15.2% -5.4%
Net Profit Margin 2.6% -6.9%
Return on Equity (ROE) 2.6% -73.2%
4. Balance Sheet & Cash Flow ICCC
Cash Generation (TTM) $7.4M -$2.5M
Cash Flow Margin 11.0% -4.9%
Net Cash / Leverage $13M Net Debt (0.44x D/E) -$319,000 Net Debt (0.90x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat IRIX
OpEx & R&D Intensity 25.1% of Rev ($17M) 41.3% of Rev ($21M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ICCC (8) vs IRIX (1)
Institutional Metric ICCC IRIX Criterion Row Edge
Market Capitalization
Scale
$97.7M $12.1M Larger Scale ICCC
Trailing P/E Ratio
Valuation
56.6x N/M Lower Multiple ICCC
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+11.5% -7.4% Higher Growth ICCC
Operating Margin (TTM)
Profitability
15.2% -5.4% Higher Margin ICCC
Net Profit Margin
Profitability
2.6% -6.9% Higher Margin ICCC
Return on Equity (ROE)
Capital Efficiency
2.6% -73.2% Higher ROE ICCC
52-Week Range Position
Momentum
91% ($5–$12) 8% ($1–$2) Stronger Trend ICCC
Beta / 30D Volatility
Risk Regime
0.24β · 46% Vol 0.66β · 58% Vol Lower Realized Risk ICCC
Unified Institutional Score
Composite Signal
43.8 / 100 (HOLD) 51.8 / 100 (HOLD) Higher Composite IRIX
Trailing 12M Revenue (USD)
Operating Scale
$67M $52M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
40.3% 35.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.6x EV/Rev 0.94x PEG · 0.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$7.4M ($13M Net Debt (0.44x D/E)) -$2.5M (-$319,000 Net Debt (0.90x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ICCC +21.8 pp
ICCC: +6.23% · IRIX: -15.57%
3M Horizon ICCC +43.06 pp
ICCC: +17.01% · IRIX: -26.05%
6M Horizon ICCC +47.48 pp
ICCC: +15.24% · IRIX: -32.24%
1Y Horizon ICCC +111.25 pp
ICCC: +88.76% · IRIX: -22.49%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ICCC Revenue IRIX Revenue ICCC Op. Margin IRIX Op. Margin Margin Leader
FY2019 $10M $40M -7.0% -20.7% ICCC
FY2020 $20M N/A -9.0% N/A ICCC
FY2021 $20M $40M 1.3% -18.1% ICCC
FY2022 $20M $60M -12.4% -13.2% ICCC
FY2023 $20M $50M -32.9% -19.3% IRIX
FY2024 $30M $50M -6.2% -17.1% ICCC
FY2025 $30M N/A 6.0% N/A ICCC
FY2026 N/A $50M N/A -4.9% IRIX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ICCC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ICCC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IRIX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IRIX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ICCC Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $97.7M market capitalization and 15.2% operating margin.
OpEx & R&D Reinvestment 25.1% of Rev ($17M)
90D Engineering Disclosures 0 Published
IRIX Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $12.1M market capitalization and -5.4% operating margin.
OpEx & R&D Reinvestment 41.3% of Rev ($21M)
90D Engineering Disclosures 0 Published

Investor FAQ ICCC vs IRIX Key Questions & Quantitative Answers

As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Iridex Corp (IRIX) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ICCC carries a Unified Composite Score of 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin), whereas IRIX carries 51.8/100 (HOLD) at $0.69 (N/M Forward P/E, -5.4% operating margin). Composite vs. Pillar Nuance: While IRIX currently prints a higher short-term Unified Composite Score (51.8/100 HOLD vs. ICCC 43.8/100 HOLD), ICCC captures the overall institutional head-to-head verdict (8–1 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (15.2% vs. -5.4% operating margin) and revenue trajectory (+11.5% vs. -7.4% YoY).

ICCC leads the Growth & Scale pillar: ICCC posts +11.5% YoY revenue growth and +259.9% YoY earnings growth on $67M TTM revenue (40.3% gross margin, 15.2% operating margin), compared with IRIX at -7.4% YoY revenue growth and +0.0% YoY earnings growth on $52M TTM revenue (35.9% gross margin, -5.4% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), ICCC cumulative revenue shifted +200.0% while IRIX shifted +25.0%. In operating R&D and SG&A reinvestment, ICCC deploys 25.1% of Rev ($17M) (0 90-day corporate R&D disclosures) versus 41.3% of Rev ($21M) (0 disclosures) for IRIX.

IRIX screens cheaper on headline valuation multiples. ICCC trades at N/M Forward P/E, 56.6x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (11.0% FCF margin), whereas IRIX trades at N/M Forward P/E, N/M Trailing P/E, 0.94x PEG, and 0.2x EV/Revenue (-4.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ICCC (2.6% ROE) versus IRIX (-73.2% ROE) capital efficiency.

In options market volatility and institutional positioning, ICCC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.24β · 46% Vol realized risk). By comparison, IRIX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.66β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.